Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2019

View Archived Issues

Another reason to vaccinate

Motor scores mislead in Parkinson's disease model

Lipac Oncology advances evaluation of TBC-1002 in bladder cancer

Mutant mouse with seizures, tremor and increased levels of neurotransmitters as an epilepsy model

Selective Nav1.7 inhibitor shows analgesic efficacy in pain mouse models

BioCryst advances phase I study of BCX-9930 for paroxysmal nocturnal hemoglobinuria

Heterozygous p.Leu47Val variant in HSPD1 causes hypomyelinating leukodystrophy

First subject dosed in phase II ADVISE study of etrasimod in atopic dermatitis

Interim results presented from pivotal phase III SIERRA study of Iomab-B in AML

Microbion announces phase Ib data for pravibismane in infected diabetic foot ulcers

MyoKardia announces promising results from phase IIa study of MYK-491

Autophagy defects caused by TRAPPC4 variant are associated with syndromic intellectual disability

First known case of jaw keratocyst in an individual with SUFU-related Gorlin syndrome

Phase II results presented for TIMP-GLIA in celiac disease

University of Texas System patents CBP and KAT3B inhibitors

Pivotal study of budesonide oral suspension in eosinophilic esophagitis achieves endpoints

Iveric Bio's phase IIb study of Zimura for geographic atrophy in dry AMD meets primary endpoint

TG reports promising data from phase II UNITY-NHL trial of umbralisib in follicular lymphoma

BioCryst Pharmaceuticals discloses complement factor D inhibitors

GlaxoSmithKline identifies new ATF-4 inhibitors

Flex Pharma synthesizes voltage-gated sodium channel blockers

New adenosine A2A receptor antagonists disclosed by BeiGene

Ziopharm and MD Anderson agree to expand TCR-T program

European Commission approves Bavencio with axitinib for first-line advanced RCC

AstraZeneca reports promising PFS data with Imfinzi and tremelimumab in stage IV NSCLC

CARB-X award supports BioVersys' development of antimicrobial therapies

At Molecular Targets meeting, a bonanza of ways to thwart "undruggable" KRAS

Clinical development of MOR-106 for atopic dermatitis ended for futility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...